Johnson & Johnson halts COVID-19 vaccine study as participant falls ill
Category: #health  | By Nikita Chaurasia  | Date: 2020-10-14 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Johnson & Johnson halts COVID-19 vaccine study as participant falls ill

 

  • Johnson & Johnson had initially planned to enroll over 60,000 participants for its phase 3 clinical trials.
  • Experts claim that clinical pauses are a common aspect and may last only a few days.

U.S.-based multinational pharmaceutical corporation Johnson & Johnson has reportedly paused the study of its COVID-19 vaccine candidate after it had an adverse effect in one of the participants. Sources close to the matter stated that the company has issued an investigation on the unexplained ailment in the participant.

Johnson & Johnson had initially planned to enroll over 60,000 participants in the U.S. as well as other countries for its phase 3 clinical trials. In this context, experts cite that given the size of the company’s COVID-19 vaccine trials, such pauses are a common aspect and may last only a few days.

Johnson & Johnson mentioned in a statement that accidents, illnesses and other adverse medical outcomes are a common part of a clinical study and its safety monitoring panel will review as well as determine the cause of the illness.

Johnson & Johnson also emphasized over the fact that its COVID-19 vaccine study is currently paused and not on a clinical hold. The American pharmaceutical giant added that it is not yet apparent whether the participant who suffered an adverse effect received the potential vaccine or a placebo.

For the record, British pharmaceutical company AstraZeneca plc had also kept its COVID-19 vaccine trials on hold earlier in September, after one of the study participants witnessed an unexpected reaction. Although the study resumed in the United Kingdom a week later, the trials are still kept on hold in the United States.

In other news, Indian biotechnology company Bharat Biotech International Ltd. has reportedly reduced the size of its phase-2 clinical study for COVID-19 vaccine candidate called Covaxin. According to experts, reducing the size of Covaxin’s clinical trial will allow Bharat Biotech to accelerate phase-2 study and possibly initiate the phase 3 trials eventually.

Source Credits –

https://www.statnews.com/2020/10/12/johnson-johnson-covid-19-vaccine-study-paused-due-to-unexplained-illness-in-participant/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...